Hemogenyx Pharmaceuticals files IND with FDA and advances European commercialization
- Reports
- 6
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Hemogenyx Pharmaceuticals submitted an IND application for its HG-CT-1 therapy to the FDA. The company also announced unaudited interim results for the six months ended 30 June 2026, noting the completion of manufacturing transition and securing regulatory clearances for both children and adults. Furthermore, the company is building physical infrastructure for early commercialization in Europe.
From tennesseedaily.com
Why it matters
The company’s achievements, including securing regulatory clearances and building commercial infrastructure, indicate it is transitioning from a clinical-stage operation toward market readiness. This progress advances the potential for the therapy to enter the European market.
From tennesseedaily.com
Who's involved
How it developed
Newest first. Tap a step to see who reported it.Therapy achieves global regulatory clearance following positive recommendations from US and European bodies.1 source
Agreement reached to evaluate delivery technology between Nitto and Hemogenyx.1 source
IND application submitted for HG-CT-1 therapy; planning early commercialization in Europe.1 source